Behind the Counter: Mastering Pseudoephedrine and Other Restricted OTC Medications
November 5th 2024Melissa Zinszer, PharmD, CDCES, explores the multifaceted role of pharmacists and healthcare providers in managing behind-the-counter medications, addressing patient concerns, optimizing over-the-counter therapy, and ensuring safe, effective treatment through careful symptom assessment and consideration of drug interactions.
Pharmacists’ Roles in MM Management
November 1st 2024Panelists discuss how pharmacists play a crucial role throughout the multiple myeloma patient journey, from diagnosis to treatment, by contributing to medication management, patient education, adverse effect monitoring, and the development and implementation of order sets and clinical pathways within electronic medical record systems, thereby enhancing treatment efficacy and patient safety.
SC vs IV Administration Methods
November 1st 2024Panelists discuss how subcutaneous (SC) administration of drugs like daratumumab offers advantages over intravenous (IV) administration in terms of reduced health care resource utilization, improved patient convenience, and potentially better treatment adherence, while also considering potential drawbacks such as injection site reactions and the need for proper training in SC administration techniques.
Strategies for Incorporating Vaccinations into Pharmacy Workflows
November 1st 2024Carrie Koenigsfeld, PharmD, FAPhA, discusses how pharmacists can incorporate RSV vaccination education and recommendations into daily pharmacy workflows, including prescription pick-ups, consultations, and routine MTM sessions.
Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7
October 25th 2024Panelists discuss how recent phase 3 trial data from PERSEUS, IsKia, and GMMG HD7 are shaping their approach to induction and consolidation therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, particularly focusing on the incorporation of CD38 antibodies into upfront treatment regimens and the potential shift from triplet to quadruplet therapies based on these pivotal trial findings.
Vaccine Hesitancy and Patient Counseling Techniques
October 25th 2024Carrie Koenigsfeld, PharmD, FAPhA, discusses her experience with concerns and perceptions contributing to RSV vaccine hesitancy among older adults, such as safety, efficacy, necessity, awareness, and cost, and she explores how pharmacists can effectively counsel patients and caregivers about RSV vaccines while tailoring communication strategies to educate older adults with low health literacy.
Shaping the Future of Pharmacogenomics: STRIPE Drives Stakeholder Consensus at Inaugural Meeting
October 24th 2024Benjamin Brown of Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) discusses his own experience as a patient with cancer and how consensus around pharmacogenomic practices can improve the lives of patients.
Challenges in Adopting Novel Therapies
October 18th 2024Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings
Real-World Considerations for New Therapies
October 18th 2024Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October 14th 2024In this interview for World Standards Week, Nakia Eldridge, PharmD, MPH, of US Pharmacopeia (USP), discusses USP's key achievements in 2024, while outlining the organization's 2025 goals.